Eli Lilly (NYSE: $LLY) is experiencing significant financial turbulence, with its stock price nearing its lowest level since February. The pharmaceutical giant has seen a 25% decline from its all-time high, entering bear market territory. The stock has dropped for three consecutive days, with a critical support level at $718. Despite the rich valuation, some investors are considering it a potential buy opportunity in the range of $683 to $715. The company has an institutional ownership of 82%, with many baby boomer pension funds heavily invested.